Correction to: High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease (Journal of the American Heart Association, (2017), 6, 7, 10.1161/JAHA.117.005699);High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease

Journal of the American Heart Association

Volumn 6, Issue 7, 2017, Pages

  Foley, T Raymond ^a   Singh, Gagan D ^b   Kokkinidis, Damianos G ^a   Choy, Ho Hin K ^b   Pham, Thai ^b   Amsterdam, Ezra A ^b   Rutledge, John C ^b   Waldo, Stephen W ^a   Armstrong, Ehrin J ^a   Laird, John R ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amputation; Critical limb ischemia; Peripheral artery disease; Statin; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT OUTCOME; AMPUTATION; BLOOD; CLINICAL PRACTICE; COMPARATIVE STUDY; CRITICAL ILLNESS; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DYSLIPIDEMIA; ENDOVASCULAR SURGERY; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PRESCRIPTION; REGISTER; RISK FACTOR; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMPUTATION; ANGIOGRAPHY; ATORVASTATIN CALCIUM; BIOMARKERS; CRITICAL ILLNESS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG PRESCRIPTIONS; DYSLIPIDEMIAS; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN-MEIER ESTIMATE; LIPIDS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; ROSUVASTATIN CALCIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 85025438766     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.118.002305     Document Type: Erratum

References (30)

1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509-1526.
2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, Goto S, Liau C-S, Richard AJ, Röther J, Wilson PWF; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.
3. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
4. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241-245.
5. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20, 536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645-654.
6. Feringa HHH, Karagiannis SE, van Waning VH, Boersma E, Schouten O, Bax JJ, Poldermans D. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007;45:936-943.
7. Aiello FA, Khan AA, Meltzer AJ, Gallagher KA, McKinsey JF, Schneider DB. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg. 2012;55:371-380.
8. Westin GG, Armstrong EJ, Bang H, Yeo K-K, Anderson D, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682-690.
9. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35:2864-2872.
10. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, White CJ, White J, White RA, Antman EM, Smith SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-e654.
11. Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, Gislason GH, Berger J, Torp-Pedersen C, Fosbol EL. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease. Underuse remains. Circulation. 2012;126:1345-1354.
12. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF; College American of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;2014(63):2889-2934.
13. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
14. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
15. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
16. Spring S, Simon R, van der Loo B, Kovacevic T, Brockes C, Rousson V, Amann-Vesti B, Koppensteiner R. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost. 2008;99:182-189.
17. 335-2012: Standardized difference: an index to measure the effect size between two groups-335-2012.pdf. Available at: http://support.sas.com/resources/papers/proceedings12/335-2012.pdf. Accessed March 3, 2017.
18. Investigators TSP by AR in CL (SPARCL). High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
19. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
20. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III-39-III-43.
21. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
22. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-2060.
23. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
24. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tønnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J (Clin Res Ed). 1986;293:1137-1140.
25. Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015;101: 356-362.
26. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017;2:47.
27. Sikkink CJ, van Asten WN, van 't Hof MA, van Langen H, van Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med. 1997;2:169-173.
28. Olin JW, Allie DE, Belkin M, Bonow RO, Casey DE, Creager MA, Gerber TC, Hirsch AT, Jaff MR, Kaufman JA, Lewis CA, Martin ET, Martin LG, Sheehan P, Stewart KJ, Treat-Jacobson D, White CJ, Zheng Z-J. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. J Am Coll Cardiol. 2010;56:2147-2181.
29. O'Connor PJ, Gray RJ, Maciosek MV, Fillbrandt KM, DeFor TA, Alexander CM, Weiss TW, Teutsch SM. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. Prev Chronic Dis. 2005;2. Available at: https://www.cdc.gov/pcd/issues/2005/jul/04_ 0146.htm. Accessed June 8, 2016.
30. Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin use in outpatients with obstructive coronary artery disease. Circulation. 2011;124:2405-2410.